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Abstract
Androgen receptor (AR) function is critical for the development of male reproductive organs, muscle, bone and other
tissues. Functionally impaired AR results in androgen insensitivity syndrome (AIS). The interaction between AR and
microRNA (miR) signaling pathways was examined to understand the role of miRs in AR function. Reduction of androgen
levels in Sprague-Dawley rats by castration inhibited the expression of a large set of miRs in prostate and muscle, which was
reversed by treatment of castrated rats with 3 mg/day dihydrotestosterone (DHT) or selective androgen receptor
modulators. Knockout of the miR processing enzyme, DICER, in LNCaP prostate cancer cells or tissue specifically in mice
inhibited AR function leading to AIS. Since the only function of miRs is to bind to 39 UTR and inhibit translation of target
genes, androgens might induce miRs to inhibit repressors of AR function. In concordance, knock-down of DICER in LNCaP
cells and in tissues in mice induced the expression of corepressors, NCoR and SMRT. These studies demonstrate a feedback
loop between miRs, corepressors and AR and the imperative role of miRs in AR function in non-cancerous androgen-
responsive tissues.
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Introduction
Nuclear hormone receptors represent the largest family of ligand-
activated transcription factors and play pivotal roles in diverse
biological functions[1]. For example, androgen (AR) and estrogen
(ER) receptors are essential for reproduction, bone, and muscle
development, while glucocorticoid receptor regulates inflammation
and glucose homeostasis[2–4] These roles make the drugs that target
nuclear hormone receptors as one of the largest classes of drugs[5].
The long-held belief that nuclear hormone receptors mediate
the pharmacologic actions of hormones solely through direct DNA
binding has unraveled over the last decade revealing an even more
complex signaling cascade.
AR is known to regulate gene expression through direct DNA
binding as well as through protein-protein interaction[6,7]. AR
interacts with coactivators and corepressors, which are large classes of
proteins that augment or suppress receptor function, respectively[7–
9]. These proteins are critical for AR function and knockout of these
proteins produce a wide range of phenotypes in animal models[10].
microRNAs (miRs) are short 22 nucleotide non-translatable
RNAs that bind to the 39 untranslated region (UTR) of target
genes and repress or degrade mRNAs. miRs are synthesized as
primary miRs (pri-miRs) by RNA Pol II, which are converted to
mature miRs by the RNAse enzymes, Drosha and DICER[11,12].
In the last few years, there is increasing inquisitiveness regarding
the importance of miRs in normal development and pathological
transformation of tissues[13–16]. Moreover, due to their presence
in serum and owing to their stability, miRs are being evaluated as
biomarkers for the early detection of several diseases including
cancer and obesity[17–19]. Despite these developments, ligand- or
drug-dependent miR regulation and their significance in nuclear
hormone receptor function has not been demonstrated clearly.
Recent studies in mammalian tissues and drosophila indicated the
involvement of miRs in nuclear hormone receptor function[20,21].
Yamagata et al showed that estrogen-ER-a complexes interacted with
Drosha and down-regulated the expression of a subset of miRs lead-
ing to altered ER function[20]. Similar studies, utilizing in vitro
characterization in prostate cancer cells, identified androgen responsive
elements (AREs) in the promoter of miR-21 and miR-125b[22,23].
In this study, we investigated the importance of miRs in AR
function. Androgens up-regulated the expression of a large set of
miRs in prostate and levator ani muscle in rats. Tissue-specific
knockout of Dicer in micecompletely impaired AR function leading
to an androgen-insensitivity syndrome. This work clearly demon-
strates that miRs are mediators of AR function and the existence of
a possible feedback loop between miRs, AR and corepressors.
Materials and Methods
The animal studies were conducted under the guidance and
approved protocols of the Animal Care and Use Committee
(ACUC) of the University of Tennessee. The pharmacodynamic
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protocol (approval ID 1673) of the ACUC of University of
Tennessee. The Dicer knockout study was performed under the
approved protocol (approval ID 1763) of the ACUC of University
of Tennessee.
Animal pharmacodynamic experiment
The pharmacodynamic study was performed as published
earlier under the approved protocol (approval ID 1673) of the
Animal Care and Use Committee of University of Tennessee [6].
Briefly, five male Sprague Dawley rats per group (250 g) from
Harlan (Indianapolis, IN) were treated subcutaneously for 14 days
with 3 mg/day of DHT, SARM-1, SARM-2, SARM-3 or vehicle.
Dosing solutions were prepared daily by dissolving the drugs in
dimethyl sulfoxide (DMSO) and diluting in polyethylene glycol
300 (PEG 300). At the end of 14 days, the animals were sacrificed,
weights of prostate and levator ani measured and the tissues
collected for RNA isolation.
RNA Analysis and reverse transcriptase Polymerase
Chain Reaction. LNCaP cells were plated at 10,000 cells per
well of a 96 well plate in RPMI supplemented with 1% csFBS or in
full serum. The cells were maintained for 3 days and were treated
with vehicle, or AR ligands. RNA was isolated using cells-to-ct kit
(Applied Biosystems) and the expression of various genes were
measured using TaqMan primer probe mix (Applied Biosystems)
on an ABI 7900 realtime PCR machine. The expression of
individual genes was normalized to GAPDH levels. For siRNA
experiments, LNCaP cells were plated at 10,000 cells/well in
Accell siRNA transfection medium and transfected with Accell
DICER- or cyclophilin -siRNA (Dharmacon Inc., Lafayatte, CO).
Co-Immunoprecipitation
Cell extracts were prepared in homogenization buffer (0.05 M
potassium phosphate, 10 mM sodium molybdate, 50 mM sodium
fluoride, 2 mM EDTA, 2 mM EGTA, and 0.05% monothiogly-
cerol [pH 7.4] containing 0.4 M NaCl and protease inhibitors
[1 mg each of aprotinin, leupeptin, antipain, benzamidine HCl,
and pepstatin/ml], 0.2 mM phenylmethylsulfonyl fluoride, and
1 mM sodium vanadate) by three freeze-thaw cycles. Immuno-
precipitation was carried out as follows. Briefly, 100 ml of a 1:1
slurry of protein A-Sepharose beads in 16TE (0.01 M Tris and
0.001 M EDTA) was incubated for overnight at 4uC with 5 mgo f
DICER-1 antibody (DICER A-2 mouse monoclonal antibody
from SantaCruz biotechnology). The beads were washed with 16
TE, and incubated overnight at 4uC with 100 mg of protein extract
in 400 ml of the lysis buffer without salt. The beads were then
washed for 5 min once each with high-salt buffer (0.1% sodium
dodecyl sulfate [SDS], 1% Triton X-100, 2 mM EDTA, 20 mM
Tris HCl [pH 8.1], 0.5 M NaCl), low-salt buffer (same as high-salt
wash buffer but with 0.15 M NaCl), and 16 TE (10 mM Tris
HCl, 1 mM EDTA; pH 8.0). The immunoprecipitated proteins
were extracted with 26 Laemmli buffer, separated on an SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) gel, and the AR
band detected by Western blotting.
Chromatin Immunoprecipitation Assay (ChIP). ChIP
assays were performed as described previously[24]. Briefly,
proteins were cross-linked by incubation with 1% formaldehyde
(final concentration) at 37uC for 10 min and immunoprecipitated
with 5 mg of NCoR or SMRT antibody (Santacruz Biote-
chnology) and protein A sepharose, rotating overnight at 4uC.
DNA-protein complexes were obtained by extracting the beads
with 50 ml of freshly prepared extraction buffer (1% SDS, 0.1 M
NaHCO3) three times. Cross-linking of the DNA protein
complexes was reversed by incubating at 65uCf o r6h .T h e
DNA was extracted with a QIAquick PCR purification kit
(QIAGEN, Valencia, CA) in 25 ml final volume of TE and the
recruitment was detected by realtime PCR using primers and
probe described earlier[6].
Serum RNA isolation
Total RNA was purified from rat serum using Qiagen
miRNeasy Mini Kit with modifications (Qiagen, Valencia,
CA). Briefly, 200 ml of serum was homogenized in 800 mlo f
Qiazol Lysis reagent, and mixed with 160 ml of chloroform.
Eleven fmol each of two synthetic C. elegens miRNAs was spiked
into the aqueous phase before precipitation with 1.5 volumes of
100% ethanol. Total RNA was eluted in 40 mlo fR N a s e - f r e e
water.
Reverse transcription and qPCR for tissues
Total RNA (500 ng) was isolated using Qiagen RNA extraction
columns and primed for 312 mouse miRNAs and 4 reference
genes using the TaqMan microRNA Assay protocol (Applied
Biosystems). Reverse transcription was performed as follows: 40
cycles of 16uCf o r2m i n / 4 2 uC for 1 min/50uC for 1 sec followed
by 85uC for 5 min. cDNA was diluted 50-fold and 1 mLw a su s e d
in a 5 mL qPCR to assay the 312 miRNAs and 4 reference genes
in 384 well plates using standard conditions (single replicate).
Data are presented as 2
2DC
T using 18S rRNA as the reference
gene.
Reverse transcription and qPCR for serum
The total RNA that was eluted from the Qiagen miRNeasy
column (3.75 ml) was primed for 312 mouse miRNAs, 2 C. elegans
miRNAs and 4 additional reference genes in a 15 ml reaction using
the TaqMan MicroRNA Assays (Applied Biosystems). Reverse
transcription was performed by 40 cycles of 16uC 2 mins/42uC
1 min/50uC 1 sec/followed by 85uC for 5 mins. The cDNA
(2.5 ml) pre-amplified in a 25 ml reaction following the Applied
Biosystems Megaplex pre-amplification protocol for microRNA.
Pre-amplification was performed at 95uC/10 min, 55uC/2 min
and 72uC/2 min and then 12 cycles of 95uC/15 sec and 60uC/4
minutes. The pre-amplified cDNA was diluted 1:4 in 0.1X TE
buffer (pH 8.0), a aliquot of which was further diluted 1:50 and
1 mL was used in a 5 mL qPCR using standard conditions to
profile 312 mouse miRNAs and the 6 reference genes (single
replicate). Data are presented as 2
2DC
T using the mean of the 2 C.
elegans spike in oligos as a reference.
Statistics and Ingenuity pathway analysis
For downstream statistical analysis, normalized expression data
were imported in TIGR MeV[25]. Permutations based Students
T-tests[26] and ANOVA[27] were performed to determine
differentially expressed miRNAs between the control and
experimental groups with at least 10000 permutations per analysis.
miRs that are significantly different from castrate vehicle treated
animals at p#0.05 were plotted as heatmaps. Two dimensional
hierarchical clustering[28] was done using Euclidean Distance and
Pearson Correlation; clusters of differentially expressed miRNAs
were visualized using heatmaps.
Systems biology analysis of predicted targets of co-expressed
miRNAs was performed using our methodology published
elsewhere[29]. Briefly, a union of predicted targets for each of
co-expressed miRNAs was generated using target prediction
algorithm MicroCosm Targets Version 5[30]. A statistical
enrichment analysis of functional categories and pathways were
performed using Ingenuity Pathway Analysis system IPA 6.0
miRNAs Mediate Androgen Action
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and pathways that are significantly enriched with targets of
differentially expressed miRNAs (p#0.05) were presented as a bar
graph. Pathways enriched with miRNA targets were selected for
further analysis. Expected changes in expression level of predicted
targets were overlaid onto pathway diagram by assigning
expression changes proportional to the number of miRNAs that
are targeting the same transcripts. An overall effect of changes in
expression of miRNAs on expression level of predicted targets was
estimated as a sum of increase of expression due to down
regulation of corresponding miRNAs and decrease of expression
due to down regulation of other miRNAs. Overall effect of
changes in expression was visualized using color gradient for
overlay of predicted expression changes onto pathway diagrams
(Supplemental Figures). These estimates of hypothetical changes of
gene expression were used solely for purpose of prioritizing
predicted targets and narrowing down list of predictions in order
to select those that are most likely to be affected in experimental
groups of animals and would be more reliable candidates for
validation experiments.
DICER
2/2 mice experiments
All animal protocols were approved by Animal Care and Use
Committee (University of Tennessee, Memphis) and the
experiments were conducted under the approval ID 1763 of
University of Tennessee ACUC. MMTV-cre male and DICER
flox female mice were obtained from Jax labs (Bar Harbor,
M a i n e )a n dw e r eb r e dt o g e t h e rt oo b t a i nD I C E R
+/2 F1
generation. F1 generations were bred together to secure F2
generations. Tail snips were genotyped according to Jax labs
protocol and F2 mice that were positive for cre
+/+ and null for
DICER
2/2 were used in the pharmacodynamic experiments.
Tissue specific expression of genes was performed using realtime
PCR primers and probes.
Results
Androgen responsive tissues express distinct sets of miRs
Earlier studies in mice demonstrated that miR expression differs
tissue specifically, leading to speculation that differences in miR
expression contribute to the characteristic phenotype of these
tissues[31]. Androgen-regulated tissues are morphologically and
functionally different from one another raising the possibility of
distinct miR expression patterns. Since castration of rats leads to
regression of androgen-responsive tissues like the prostate and
levator ani muscle, changes in the expression of any genes or miRs
that occur after castration can be considered to be dependent on
circulating androgens[32,33]. miR profiling in intact rats demon-
strated that prostate and levator ani express distinct sets of miRs
(Fig. 1A). miRs that are highly expressed in one tissue are not- or
weakly- expressed in the other tissue and vice versa. For example,
miRs- 206, -133a, -133b, and -1 are expressed robustly in levator
ani muscle, but weakly in prostate. On the other hand, miRs-021, -
200a, -200b, and -200c are highly expressed in prostate, but not in
levator ani muscle. The above mentioned miRs are indicated in
Fig. 1A.
Measurement of hormone levels in serum of animals treated
with vehicle or SARMs indicated that both SARM-1 and SARM-
2 functioned similar to endogenous hormone such as DHT, by not
altering the serum testosterone, but by completely inhibiting the
castration induced increases in serum luteinizing hormone and
follicle stimulating hormone (supplementary table S1). This
indicates that these SARMs function directly through AR at the
target tissue and not by altering serum hormone levels.
Androgen treatment up-regulates the expression of a
large set of miRs in prostate
To understand the effect of circulating androgens on miR
expression in prostate and muscle, Sprague Dawley rats were
sham operated and treated with vehicle or castrated and treated
subcutaneously for 14 days with vehicle, dihydrotestosterone
(DHT), selective androgen receptor modulators, SARM-1 and
SARM-2, or an inactive structurally similar, SARM-3. To obtain
conclusive results from this study, we utilized AR ligands with
varying potency, tissue selectivity and structural diversity[34].
Tissue weights taken at the end of 14 days demonstrated varying
levels of androgenic (maintenance of prostate and seminal vesicles
weights) and anabolic (maintenance of levator ani muscle weight)
effects of these AR ligands (Fig. 1B). While DHT elicited equally
potent androgenic and anabolic effects, as evident from the largest
increases in prostate, seminal vesicle and levator ani muscle
weight, SARM-1 and SARM-2 delivered better anabolic than
androgenic effects confirming their tissue selectivity. For example,
note that SARM-2 increased levator ani muscle weight to a similar
magnitude as DHT, but only restored the prostate to ,50% of the
size observed in DHT-treated animals. As expected, the inactive
SARM-3 had no effect on any tissue.
Comparison of the miR profiles in prostate of vehicle-treated-
sham-operated intact animals versus vehicle-treated- castrated
animals (Fig. 2A) showed a striking reduction in a large subset of
miRs upon castration, indicating that endogenous androgens
maintained the levels of miRs and that expression of miRs was
significantly reduced upon interrupted androgen supply. Only a
small subset of miRs was up-regulated 14 days after castration.
As castration clearly down-regulated a large subset of miRs in
prostate, we examined the effects of androgen treatment of
castrated rats to further prove that miR expression was androgen
regulated. miR profiling in prostate of rats treated with AR ligands
demonstrated that the increase in prostate weight was associated
with an increase in miR expression (Fig. 2B). While DHT, which
maximally increased prostate weights, elicited the greatest increase
in miR expression, partial androgenic SARM-1 elicited only a
marginal increase in miR expression in the prostate. On the other
hand, SARM-2 elicited a mixed miR profile in the prostate. While
many SARM-2 regulated miRs were intermediate in expression
between SARM-1 and DHT, some SARM-2 elicited changes were
more similar to DHT-treated and sham-operated intact groups.
miR expression was maximum in the sham-operated intact
animals as compared to the vehicle-treated castrated animals.
Not only did the group clustering match perfectly with the
androgenic response, but the unsupervised hierarchical clustering
of individual animals also matched well with the observed changes
in prostate weight (Fig. 2B inset). The inactive SARM-3 failed to
alter miR expression indicating the imperative need for AR-
binding and -activity to alter miR expression. The right panels of
Fig. 2B are representative bar graphs of miRs significantly
regulated in prostate. A complete list of regulated miRs (Table
S2) and a Venn diagram indicating ligand- dependent distribution
of miRs (Figure S1) are depicted in the supplementary figures and
tables.
In order to measure the tissue specificity of miRs regulation,
expression of miRs was profiled in the liver of rats treated as
indicated above. Interestingly, none of miRs were regulated in
liver by any of the tested ligands (data not shown), indicating the
specificity to androgen responsive tissues such as prostate and
levator ani.
Ingenuity pathway analyses to identify affected functional and
canonical pathways showed that SARM-1, SARM-2 and DHT
activated overlapping but distinct miRs and consequently gene
miRNAs Mediate Androgen Action
PLoS ONE | www.plosone.org 3 October 2010 | Volume 5 | Issue 10 | e13637Figure 1. Androgen responsive tissues, prostate and levator ani muscle, express different sets of miRs. A. RNA was extracted from
prostate and levator ani muscle of intact Sprague Dawley rats (n=5; 200 g weight) and the expression of 312 miRs was profiled using realtime PCR.
miRs that are statistically different (P,0.05) between the two groups are expressed in the heatmap. P1-P5=prostate of animals 1–5; LA1-
LA5=levator ani of animals 1–5. B. Pharmacologic effects of AR ligands. Sprague Dawley rats (n=5; 200 g weight) were castrated and treated
subcutaneously for 14 days with vehicle (open bars), 3 mg/day SARM-1 (dotted bars), SARM-2 (hatched bars), an inactive SARM-3 (grey bars) and DHT
(black bars). Intact vehicle treated animals are represented by checked bars. At sacrifice, organs were weighed and expressed as raw organ weights.
Values are expressed as average 6 S.D.
doi:10.1371/journal.pone.0013637.g001
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regulated by each ligand varied tremendously. While SARM-1
regulated the least number of functional and canonical pathway
genes, the highly androgenic DHT altered the pathway genes
remarkably. Interestingly and similar to changes noted in prostate
weight and miRs expression, the number of pathway genes
regulated by SARM-2 was intermediate between SARM-1 and
DHT regulated genes. The Ingenuity analysis indicated that Wnt
signaling pathway is the major canonical pathway affected by the
AR ligands in prostate (Figure S2). While DHT activated (red)
several genes, SARM-2 predominantly inhibited (green) the genes
in this pathway. Validation of the Wnt signaling pathway in the
prostate of rats indicated that DHT altered the expression of
several genes in this pathway validating the prediction based on
the altered miRs (Table S3).
AR ligands alter expression of miRs in levator ani muscle
Prostate and other secondary sexual organs are bonafide direct
target tissues of androgens[35]. Though androgens alter muscle
function and composition, this area of research lacks mechanistic
characterization and several researchers believe that androgens act
through other anabolic pathways like insulin like growth factor-1
to promote muscle growth[36]. We profiled miRs in an androgen-
responsive AR expressing muscle, levator ani[37]. Similar to the
effect in prostate, SARM-3 failed to alter the expression of any
miR compared to vehicle treated-castrate animal controls (Fig. 3A
and 3B). Unsupervised hierarchical clustering of individual
animals demonstrated that the affected miRs did not correlate
well with the anabolic effects on levator ani muscle (Fig. 3A).
While intact or sham operated- and DHT- treated animals
clustered to the extreme right in the heatmap, SARM-2-, SARM-
1- and vehicle- treated castrate animals clustered together
indicating that, unlike prostate, no consistent trend was observed
(Fig. 3A). However, clustering of the groups correlated well with
the anabolic effects, with castrate controls clustered at one end and
the sham-operated intact group clustered at the other end of the
heatmap (Fig. 3B). Castration significantly reduced most of the
miRs in levator ani indicating that, similar to prostate, miR
expression in muscle is androgen regulated. However, unlike
prostate, treatment with AR ligands failed to produce a consistent
pattern of miR regulation in levator ani muscle (Fig. 3B). A list of
regulated miRs (Table S4) and a Venn diagram indicating the
ligand-dependent distribution of miRs (Figure S3) for muscle are
depicted in the supplementary figures and tables.
Ingenuity pathway analyses to identify the functional and
canonical pathways showed that the three AR ligands affected
similar pathways (Fig. 3C). Unlike the prostate, the number of
genes altered by each ligand was almost similar. The major
pathway affected by the AR ligands in muscle was the
ERK:MAPK signaling pathway (Figure S4), but the genes of this
pathway were not consistently regulated by the ligands. DHT and
SARM-2 activated or repressed the genes similarly. The lack of
separation between DHT and SARM in an anabolic tissue is in
concordance with our earlier observations in cell lines[6] and
pharmacologic data in rats showing the ability of SARMs to mimic
the anabolic effects of DHT in levator ani muscle[38].
Functional role of miRs in androgen action
Since the AR ligands altered miR expression with near-perfect
correlation to andogenicity, we performed in vitro and in vivo
mechanistic studies to determine the functional role of miRs in
prostate. Our goal was to determine whether the observed changes
in miR expression caused or were the result of the observed
changes in tissue size (i.e., were the changes in miR expression
imperative for AR function or biomarkers of AR function in these
tissues?) (Figure S5).
To test these hypotheses, the RNAse, DICER, was inhibited in
LNCaP prostate cancer cells, using siRNA. DICER, instead of
Drosha, was targeted in these studies to understand the
importance of pre-miRs, if any, in androgen action. DICER
siRNA achieved a more than 70% knockout of DICER compared
to the control siRNA (Fig. 4A right panel). Interestingly, inhibition
of miR synthesis using DICER siRNA completely abrogated the
induction of PSA gene expression by DHT (Fig. 4A left panel).
Since AR and DICER are localized in the cytoplasm and AR
shuttles into the nucleus upon ligand binding, interaction between
the two proteins was analyzed in the presence or absence of a
strong (DHT) or a weak (SARM-1) AR ligand using co-
immunoprecipitation studies. Though both proteins were localized
in the cytoplasm, there was no interaction between AR and
DICER in the absence of ligand[39,40]. Strikingly the two
proteins interacted in the presence of SARM-1 or DHT (Fig. 4B).
This indicates that ligand-induced changes in conformation of AR
promote its interaction with DICER. Functional consequences of
this interaction and the site of this interaction are being analyzed
currently.
Plausible hypothesis and confirmation for the
involvement of corepressors
Since miRs inhibit translation or degrade mRNA of a target
gene, we hypothesized that the observed inhibition of AR function
upon reduced miR synthesis was an indication that the miRs
function as inhibitors of AR repressors. Nuclear receptor
corepressor (NCoR) and silencing mediator of retinoid and
thyroid receptor (SMRT) are two well-characterized repressors
of AR function[41]. It is feasible that AR in the presence of ligand
increases miR- synthesis and -binding to the 39UTR of NCoR and
SMRT, leading to degradation of the mRNAs for these two
corepressors (Fig. 4C1). Degradation of NCoR and SMRT would
in turn increase the transcription and translation of AR target
genes. On the other hand, in the absence of DICER, miR
synthesis and binding to the 39UTR of corepressors would be
Figure 2. Androgen Receptor ligands alter the expression of miRs in prostate. A. Castration altered miR expression in prostate. RNA was
extracted from prostate of rats that were sham operated (Intact) or castrated (ORX) and treated subcutaneously with vehicle for 14 days. miR
expression was profiled using realtime PCR and miRs that are statistically different (P,0.05) between the two groups are expressed in the heatmap.
(n=5). B. Treatment of castrated rats with AR ligands altered miR expression in prostate. Sprague Dawley rats (n=5; 200 g weight) were sham
operated and treated subcutaneously with vehicle (Intact) or castrated and treated subcutaneously for 14 days with vehicle (ORX VEH), 3 mg/day
SARM-1, SARM-2, an inactive SARM-3 or DHT. RNA from prostate was extracted, expression of 312 miRs was profiled and the miRs that are statistically
different (P,0.05) from vehicle-treated castrate animals are expressed in the heatmap. ORX vehicle in the heatmap represents pooled data from
vehicle and SARM-3 treated castrate animals. Values are expressed as an average with n=5. The inset to the right of the heatmap represents the
clustering of the individual animals. The numbers in brackets are animal numbers. The bar graphs are representative miR expressions selected from
the heatmap. Values are expressed as average 6 S.D. (n=5). C. Ingenuity pathway analyses. The predicted targets of differentially expressed miRs
were classified into major functional (left chart) and canonical (right chart) pathways using Ingenuity software. The bars represent pathways
corresponding to the miR functional profiles of SARM-1, SARM-2 and DHT treated prostates in that respective order.
doi:10.1371/journal.pone.0013637.g002
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PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13637Figure 3. Androgen Receptor ligands alter the expression of miRs in levator ani. A and B. Sprague Dawley rats (n=5; 200 g weight) were
sham operated (Intact) and treated subcutaneously with vehicle or castrated and treated subcutaneously for 14 days with vehicle (ORX VEH (A); Cntrl
Aver (B)), 3 mg/day SARM-1, SARM-2, an inactive SARM-3 or DHT. RNA from levator ani was extracted and the expression of 312 miRs were profiled
and the miRs that are statistically different (P,0.05) from vehicle treated castrate animals are expressed in the heatmap. Values are expressed as an
average with n=5. (B). Clustering of individual samples are given in panel A. The numbers in bracket are numbers of animals. ORX vehicle in the
heatmap represents pooled data from animals treated with vehicle and SARM-3. C. Ingenuity pathway analyses. The predicted targets of differentially
expressed miRs were classified into major functional (left chart) and canonical (right chart) pathways using Ingenuity software. The bars represent
pathways corresponding to the miR functional profiles of SARM-1, SARM-2 and DHT treated levator ani muscle in that respective order.
doi:10.1371/journal.pone.0013637.g003
miRNAs Mediate Androgen Action
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inhibition (Fig. 4C2).
As a first step to validate this hypothesis, the Sanger miR
database was searched to identify the list of miRs that bind to
NCoR and SMRT 39UTRs and compare them to the upregulated
miRs in prostate. Consistent with our hypothesis, more than 75%
of the NCoR and SMRT binding miRs published in the Sanger
database were upregulated in prostate samples of our experiment
(Table S5). To confirm experimentally, NCoR and SMRT mRNA
levels were measured in LNCaP cells transfected with DICER
siRNA. Inhibition of miR synthesis with DICER siRNA led to an
increase in transcription of both NCoR and SMRT (Fig. 4D).
Though studies using DICER siRNA confirmed that inhibition
of miR maturation increases NCoR and SMRT levels, we used
SARM-1 to determine whether a ligand that binds and recruits
AR but minimally increases miR expression would promote
recruitment. We expected this ligand to increase the recruitment
of NCoR and SMRT to an ARE. LNCaP cells were treated with
SARM-1, the SARM that minimally altered the miRs, or DHT, a
ligand that maximally altered the miRs, and the recruitment of
NCoR and SMRT to PSA enhancer was determined using a
chromatin immunoprecipitation assay (ChIP assay). Consistent
with the hypothesis, treatment of LNCaP cells with SARM-1, but
not with DHT, significantly recruited NCoR and SMRT to the
PSA enhancer (Fig. 4E), indicating that an AR ligand that
minimally increases the miR expression recruited corepressors due
to the absence of negative regulation.
Inhibition of miR maturation leads to androgen
insensitivity syndrome
Since the results in LNCaP cells strongly suggested the
importance of miRs for AR function, tissue-specific DICER
knockout animals were generated by crossing MMTV-cre mice
and DICER-flox mice. Earlier studies indicated that crossing any
flox-gene with MMTV-cre inhibits the gene expression in seminal
vesicles, prostate, breast and other hormone-dependent tis-
sues[42,43]. Mice were genotyped using a PCR-based approach
to identify the DICER
+/2 and DICER
2/2 mice. When these
mice attained 6 weeks of age, they were sacrificed and weights of
prostate, levator ani and seminal vesicles were measured. No
change in the body weight was observed in these mice (Fig. 5A).
However, the androgen-dependent tissues such as prostate,
seminal vesicles and levator ani muscle were much smaller in
the DICER
2/2 mice compared to the wildtype or DICER
+/2
mice (Fig. 5B–D). Since this phenotype correlates with androgen
insensitivity syndrome, the response of castrated mice to androgen
administration was evaluated. Six week old wildtype, DICER
+/2
and DICER
2/2 mice were castrated and treated with vehicle or
10 mg/kg/day DHT subcutaneously for 14 days and the weights
of prostate, seminal vesicles, levator ani and androgen indepen-
dent kidneys were evaluated. Similar to the intact mice, wildtype
and DICER
+/2 mice responded to DHT treatment with increase
in the weights of prostate, seminal vesicles and levator ani muscle
(Fig. 5E–H). However, DICER
2/2 mice failed to respond to
DHT treatment with little to no increase in prostate and levator
ani weights and only a partial response in seminal vesicles weight
gain. The weights of an androgen-independent tissue, kidneys,
were comparable in all the three genotypes (Fig. 5H). Tissue
specific knockout of DICER in prostate and seminal vesicles, but
not in kidney, of DICER
2/2 mice was confirmed using realtime
PCR (Fig. 6A).
Based on our hypothesis and LNCaP results, NCoR levels were
measured in prostate, seminal vesicles and kidneys. As demon-
strated using DICER siRNA in LNCaP cells, NCoR expression
was significantly higher in DICER
2/2 mice compared to wildtype
mice in prostate but not in kidneys (Fig. 6B). Interestingly, NCoR
levels were not altered in seminal vesicles, perhaps indicating
prostate specificity in its regulation.
Detection of miRs in serum miR-214 and miR-125a
Multiple age-related disorders occur due to androgen deficien-
cy, suggesting that androgen supplementation is useful to
overcome these disorders. However, one of the major concerns
related to androgen therapy is an increase in prostate proliferation
and potential effects on benign prostatic hyperplasia or subclinical
prostate cancer. To determine whether we could identify any miR
in serum that could correlate to androgen action in prostate,
serum miRs were profiled in castrated rats that were administered
with SARM-1, SARM-2 and DHT as indicated above in fig. 1, 2,
3. All the three AR ligands increased the expression of various
miRs in serum (Table S6). However, only two miRs, miR-214 and
miR-125a, positively correlated with androgen action in prostate.
Serum concentrations of both these miRs were increased by
SARM-2 and DHT, but not by SARM-1 or SARM-3. In addition,
these miRs were altered by SARM-2 and DHT in prostate. This
observation requires validation using larger sample sets. Studies to
examine the dose- and time- dependent regulation of miR-214
and miR-125a, by androgens, are ongoing in our laboratories.
Discussion
miR research is predominantly focused in oncology and little
research has been performed to understand the importance of
miRs in normal tissue development. Moreover, the significance of
miRs in hormone-action or steroid receptor-function is an
emerging field of research. The classical view of hormone action
is one that depicts ligand-bound AR being recruited to the
promoter of target genes to mediate the transcription and
translation process. The results presented in this manuscript
Figure 4. miRs are important for AR function in LNCaP cells. A. DICER siRNA abrogates AR function in LNCaP cells. LNCaP cells were
transfected with cyclophilin or DICER siRNA for 6 days and treated with vehicle or 0.01 nM DHT. Expression of PSA (left panel), DICER and cyclophilin
(right panel) was measured using realtime PCR. Values are expressed as average 6 S.D. (n=3). B. Ligand dependent interaction of AR with DICER.
LNCaP cells were serum starved for 3 days and treated with vehicle, 10 nM DHT or SARM-1 for 6 hrs. Protein was extracted and immunoprecipitated
with DICER antibody and western blotted for AR. Representative blot of n=3 is shown. C. Plausible mechanism for the regulation of AR function by
miRs. 1. In the presence of DICER, androgen treatment increases miR- synthesis and –maturation and binding to 39UTR of corepressors, NCoR and
SMRT. This in turn inhibits corepressors translation resulting in augmented AR function. 2. In the absence of DICER, miR-maturation is inhibited
leading to enhanced corepressor expression subsequently repressed AR function. D. Inhibition of miR synthesis increases NCoR and SMRT expression.
LNCaP cells were transfected with cyclophilin or DICER siRNA for 6 days and the expression of NCoR and SMRT was measured by realtime PCR. Values
are expressed as average 6 S.D. (n=3). E. SARM-1- but not DHT-treatment recruits NCoR and SMRT to PSA enhancer. LNCaP cells were serum starved
for 3 days and treated with vehicle, 0.1 nM DHT or 10 nM SARM-1 for 2 hrs. Protein was cross linked with DNA and chromatin immunoprecipitation
assay (ChIP) was performed using NCoR and SMRT antibodies. Representative of three independent experiments is shown. AR=androgen receptor;
CoA=coactivator; CoR=corepressor; GTF=general transcription factor; NCoR=nuclear receptor corepressor; SMRT=silencing mediator of retinoid
and thyroid receptors.
doi:10.1371/journal.pone.0013637.g004
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13637Figure 5. DICER null mice have impaired androgen responsiveness. A. Intact DICER null mice have smaller androgen responsive tissues.
MMTV cre and DICER flox mice were crossed to generate tissue selective DICER +/2 or DICER 2/2 mice. Body (A), prostate (B), seminal vesicle (C) and
levator ani (D) weights were measured in 6 weeks old F2 generation mice (n=2). B. Partial responsiveness of DICER homozygous null mice to DHT. Six
weeks old wildtype (n=5), DICER +/2 (n=9) and DICER 2/2 (n=5) mice were castrated and treated subcutaneously with vehicle or 10 mg/kg/day
DHT for 14 days. The animals were sacrificed and prostate (E), seminal vesicles (F), levator ani (G) and kidney (H) weights were measured and
normalized to body weights. Data is expressed as DHT-dependent fold change from the respective vehicle groups. **-significant at P,0.01 and
*-significant at P,0.05 from DHT treated wildtype animals.
doi:10.1371/journal.pone.0013637.g005
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Instead of the classical one-step model of gene activation, AR also
appears to regulate gene expression through a three-step pathway
including miR activation, corepressor suppression and DNA
interaction to elicit its action.
Though the work clearly demonstrates that androgens increase
the expression of a large set of miRs, it is possible that only a few
miRs may be mediating androgen action in prostate. miR-21 and
miR-125, which have been published to be androgen responsive
and play a role in prostate carcinogenesis, are also upregulated in
normal prostate[22,23]. Our dataset indicates that miR-21 is
highly responsive to androgen treatment in normal prostate. Even
a weakly androgenic AR ligand, SARM-1, was able to induce the
expression of miR-21 in prostate. As miR-21 was not increased in
levator ani muscle, and unregulated by the inactive SARM-3, this
could also function as a prostate-specific marker of androgen
action.
Despite these results, several questions remain unanswered. The
role of Drosha, intracellular localization of DICER, whether loss
of AR responsiveness is due to increased NCoR/SMRT
expression and binding of the upregulated miRs to NCoR and
SMRT 39UTRs are some worth mentioning. The most interesting
question is the reasons for AR to only ligand-dependently interact
with DICER during its nuclear translocation process. Since the
coimmunoprecipitation experiments were performed six hours
after ligand treatment, the time at which nuclear localization of
AR is complete, it raises the possibility that DICER completes its
miR processing quickly before translocating to the nucleus.
Moreover, the lack of interaction between unliganded AR and
DICER, despite their co-existence in the cytoplasm, suggests that
conformational changes in AR lead to its interaction with DICER.
Since the interaction took place with two different classes of AR
ligands which are capable of inducing diverse structural modifi-
cations, we speculate that only events common to both
conformations could be responsible for this interaction[44].
The cause and effect relationship between cellular proliferation
and miR expression (supplementary figure S5), whether androgens
activate miRs to proliferate the tissues or vice versa, was clarified by
the results obtained with DHT in DICER 2/2 knockout mice.
Though DHT increased the size of prostate and levator ani
comparable to the intact animals, it was unable to restore the miR
expression to that of the intact animals. This indicates the
discordance between androgen-regulated cell numbers and miR
expression as even partial restoration of miR expression was
sufficient to increase the tissue size. Similarly, prostate and levator
ani in DICER 2/2 mice did not respond to DHT treatment,
indicating that miRs mediate androgen actions to subsequently
increase cellular proliferation.
Interestingly, DICER knockdown failed to increase NCoR
expression in seminal vesicles. This could potentially be due to the
lack of complete regulation of DHT action in DICER 2/2. This
also indicates the possible tissue selective regulation of androgen
action by miRs.
A few seminal studies have been performed to understand the
role of miRs in ER biology. Similar to androgens, estrogens also
activate miRs during female reproductive development. Knockout
of DICER in uterus and ovaries rendered these mice infertile
demonstrating the importance of miRs in female reproductive
development[45,46]. The major difference between estrogen and
androgen action is that estrogens work at Drosha level, whereas
androgens appear to work at the DICER level, indicating that
even presence of pre-miRs are insufficient for androgen action.
Also, the DICER
+/2 data, similar to other publications, indicates
that presence of one allele is sufficient to rescue the phenotype of
these mice[47].
Collectively, these results explained a mechanism for androgen
action in prostate and muscle and found a tight relationship
between AR, miRs and corepressors. These studies also suggest
that miRs are indirect RNA activators of AR.
Supporting Information
Table S1 Hormone levels were measured in serum of animals
castrated and treated with vehicle, SARM-1 or SARM-2 or intact
animals treated with vehicle. Values are expressed as mean 6 S.D
(n=5).
Found at: doi:10.1371/journal.pone.0013637.s001 (0.05 MB TIF)
Table S2 Statistically significant miRs in prostate in groups
treated with vehicle or AR ligands as detailed in Fig. 2.
Found at: doi:10.1371/journal.pone.0013637.s002 (0.02 MB
PDF)
Table S3 Validation of Wnt-b-catenin pathway genes in
prostate of DHT or SARM-1 treated animals. RNA from prostate
Figure 6. A. Expression of DICER in wildtype and DICER 2/2 mice in prostate, seminal vesicles and kidney from animals described under Fig. 5E–5G.
White bars are wildtype mice and black bars are DICER 2/2 mice. B. Expression of NCoR and SMRT in wildtype and DICER 2/2 mice in prostate,
seminal vesicles and kidney from animals described under Fig. 5E–5G. White bars are wildtype mice and black bars are DICER 2/2 mice.
doi:10.1371/journal.pone.0013637.g006
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PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e13637(n=5) of vehicle- or DHT- treated castrate animals that were used
for miR profiling represented in Fig. 2 were reverse transcribed
and the expression of Wnt-b-catenin pathway genes measured
using PCR array (SA Biosciences, Frederick, MD). Statistically
different genes in DHT- treated groups compared to vehicle-
treated group are expressed.
Found at: doi:10.1371/journal.pone.0013637.s003 (0.06 MB TIF)
Table S4 Statistically significant miRs in levator ani in groups
treated with vehicle or AR ligands as detailed in Fig. 3.
Found at: doi:10.1371/journal.pone.0013637.s004 (0.08 MB TIF)
Table S5 miRs interacting with the 3’ UTR of NCoR and
SMRT (Sanger database) that are up-regulated by AR ligands in
prostate (Fig. 2).
Found at: doi:10.1371/journal.pone.0013637.s005 (0.06 MB TIF)
Table S6 Expression of miRs in serum. RNA was extracted
using Qiagen RNA extraction kits from 1 ml serum from animals
that were treated as indicated under Fig. 2. The expression of 312
miRs was profiled using realtime PCR based methods.
Found at: doi:10.1371/journal.pone.0013637.s006 (0.07 MB TIF)
Figure S1 Venn diagram of the statistically significant miRs in
prostate. miRs that are significantly altered by the treatments
described in Fig. 2 are categorized into Venn diagram.
Found at: doi:10.1371/journal.pone.0013637.s007 (0.06 MB TIF)
Figure S2 Wnt-b-catenin pathway. Genes predicted to be
targets of microRNAs regulated by DHT and SARM-2 in
prostate. Genes marked in red are predicted to be up-regulated,
genes marked in green are predicted to be down-regulated and
genes marked in white are predicted to be non-regulated as a result
of microRNA regulation by the respective ligands (see supple-
mentary statistical methods section for details).
Found at: doi:10.1371/journal.pone.0013637.s008 (0.21 MB TIF)
Figure S3 Venn diagram of statistically significant miRs in
levator ani. miRs that are significantly altered by the treatments
described in Fig. 3 are categorized into Venn diagram.
Found at: doi:10.1371/journal.pone.0013637.s009 (0.05 MB TIF)
Figure S4 ERK-MAPK pathway. Genes predicted to be targets
of microRNAs regulated by DHT and SARM-1 in levator ani
muscle. Genes marked in red are predicted to be up-regulated,
genes marked in green are predicted to be down-regulated and
genes marked in white are predicted to be non-regulated as a result
of microRNA regulation by the respective ligands (see statistical
methods section for details).
Found at: doi:10.1371/journal.pone.0013637.s010 (0.23 MB TIF)
Figure S5 Possible predicted mechanism for the regulation of
miRs by AR ligands.
Found at: doi:10.1371/journal.pone.0013637.s011 (0.08 MB TIF)
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